Biolife Sciences Stock Current Asset

BLFE Stock  USD 0.0001  0.00  0.00%   
BioLife Sciences fundamentals help investors to digest information that contributes to BioLife Sciences' financial success or failures. It also enables traders to predict the movement of BioLife Pink Sheet. The fundamental analysis module provides a way to measure BioLife Sciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioLife Sciences pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

BioLife Sciences Company Current Asset Analysis

BioLife Sciences' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.

Current Asset

 = 

Cash

+

Deposits

+

Liquid Assets

More About Current Asset | All Equity Analysis
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
Competition

In accordance with the recently published financial statements, BioLife Sciences has a Current Asset of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Medical Instruments & Supplies industry. The current asset for all United States stocks is 100.0% higher than that of the company.

BioLife Current Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioLife Sciences' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BioLife Sciences could also be used in its relative valuation, which is a method of valuing BioLife Sciences by comparing valuation metrics of similar companies.
BioLife Sciences is currently under evaluation in current asset category among its peers.

BioLife Fundamentals

About BioLife Sciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze BioLife Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLife Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLife Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in BioLife Pink Sheet

BioLife Sciences financial ratios help investors to determine whether BioLife Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLife with respect to the benefits of owning BioLife Sciences security.